Transcranial Magnetic Stimulation in the Treatment of Stimulant Use Disorders

Kathleen Brady, MD, PhD

ASAM Annual Conference, Dallas, Texas, April 6, 2024



Disclosure Information (Required)

TMS in Stimulant Use Disorders

April 6, 2024

Kathleen Brady, MD, PhD

No Disclosures






Learning Objectives (Suggested)

- To learn about basic principles underlying transcranial magnetic stimulation (TMS)
- *To learn about data to date supporting the use of TMS in the treatment of stimulant use disorders
- To discuss "next steps" in exploration of the use of TMS in the treatment of stimulant use disorders



What Is TMS?





TRANSCRANIAL MAGNETIC STIMULATION

Non-invasive form of brain stimulation - changing magnetic field is used to cause electric current in specific brain regions through electromagnetic induction

George MS. Sci Am. 2003;289:66-73.

Behavioral and Brain effects are frequency dependent

Frequency dependent modulation of cortical targets

High Frequency (10Hz) higher cortical excitability Amplified neural response

Intermittent
Theta Burst


Low Frequency (1Hz)

Continuous
Theta Burst


lower cortical excitability

Attenuated neural response

Standard, fixed rate TMS





Accelerated, theta burst TMS






Theoretical Constructs for Treating Cue-induced craving







Approach

Executive Control Loop

LTP-like stimulation

1-5Hz

10-20 Hz

iTBS



Limbic Arousal Loop **Example**

Stimulation in Addiction

(Sailing and Martinez, Neuropharm; 2016)

"an acute effect on craving for drugs and alcohol... few studies investigating relapse or use"

Various regions stimulated

Mechanism not well understood

Great potential – further investigation needed

Table 1 Transcranial Magnetic Stimulation (TMS)

Drug	Treatments	n	Target	Stimulation	Outcome measures	Effect	Citation
Nicotine	1	11	L DLPFC	10,20 Hz, 90,100% MT	Craving	\downarrow	Johann et al, 2003
	1	16	L DLPFC	10 Hz, 100% MT	Cue-induced craving	\downarrow	Li <i>et al</i> , 2013a, b
	2	14	L DLPFC	20 Hz, 90% MT	Craving Ad libitum smoking	No effect ↓	Eichhammer <i>et a</i> l, 2003
	1	14	L DLPFC	10 Hz, 90% MT	Cue-induced craving EEG delta	\(\dagger \)	Pripfl <i>et al</i> , 2014
	1	10	L DLPFC	1 Hz, 110% MT	Cue-induced craving fMRI: ACC, OFC, VS	\downarrow	Hayashi <i>et al</i> , 2013
	1	15	SFG SFG MOC	1 Hz, 90% MT 10 Hz, 90% MT 1, 10 Hz, 90% MT	Cue-induced craving Cue-induced craving Cue-induced craving	No effect ↓ No effect	Rose <i>et al</i> , 2011
	10	48	L DLPFC	10 Hz, 100% MT	Cue-induced craving Cigarette consumption	\downarrow	Amiaz <i>et al</i> , 2009
	20, w therapy	15	L,R DLPFC	20 Hz, 90% MT	Craving Smoking	↓ No effect	Wing et al, 2012
	15	35	L DLPFC	10 Hz, 110% MT	Smoking	\downarrow	Prikryl et al, 2014
	13, h-coil, w/cues	115	PFC, insula PFC, insula	1 Hz, 120% MT 10 Hz, 120% MT	Cigarette consumption Cigarette consumption	No effect ↓	Dinur-Klein <i>et al</i> , 2014
Alcohol	10	45	R DLPFC	10, Hz, 110% MT	Craving	\downarrow	Mishra et al, 2010
	10	20	R and L DLPFC	10, Hz, 110% MT	Craving	\downarrow	Mishra et al, 2015
	1	31	R DLPFC	20 Hz, 110% MT	Craving (lab) Craving (home)	No effect No effect	Herremans <i>et al</i> , 2012
	1	29	R DLPFC	20 Hz, 110% MT	Craving Response inhibition	No effect ↑	Herremans <i>et al</i> , 2013
	1	19	L DLPFC	20 Hz, 90% MT	Craving Depressive symptoms Alcohol cue attention	No effect No effect ↓	Hoppner <i>et al</i> , 2011
	20, h-coil	11	MPFC LPFC	20 Hz, 120% MT	Craving	\downarrow	Rapinesi <i>et al</i> , 2015
	10	18	MPFC	20 Hz, 120% MT	Craving Depressive symptoms	\(\dagger	Ceccanti <i>et al</i> , 2015
Cocaine	1	6 6	R DLPFC L DLPFC	10 Hz, 90% MT 10 Hz, 90% MT	Craving Craving	↓ No effect	Camprodon <i>et al</i> ,2007
	10	36	L DLPFC	15 Hz, 100% MT	Craving	\downarrow	Politi et al, 2008
	1	11	MPFC	cTBS, 110% MT	Craving	\downarrow	Hanlon <i>et al</i> , 2015a, b
Methamph.	1	10	L DLPFC	1 Hz, 100% MT	Craving	\uparrow	Li <i>et al</i> , 2013a, b

Modulating Neural Circuits with Transcranial Magnetic Stimulation: Stimulant Use Disorder (Hanlon et al., Pharmacol Review, 2018)

Author	Drug of Abuse	Sample Size	Site of TMS	Frequency	Sessions	Behavioral Effect?	Active Sham Control
Camprodon et al. (2007)	Cocaine	6	L/R DLPFC	10 Hz	1	Yes	Within subject
Hanlon et al. (2015b)	Cocaine	11	LvMPFC	cTBS	6^a	Yes	Within subject
Hanlon et al. (2017) Politi et al. (2008)	Cocaine Cocaine	25 36	LMPFC LDLPFC	cTBS 15 Hz	6º 10	$\mathop{\mathrm{Yes}}_{\mathop{\mathrm{Yes}}}$	Within subject No
Rapinesi et al. (2016)	Cocaine	7	L DLPFC ^b	20 Hz	12	Y_{es}	Between groups
Bolloni et al. (2016)	Cocaine	10	Bilat PFC/Ins ^b	10 Hz	12	No	Between groups
Terraneo et al. (2016)	Cocaine	32	L DLPFC	15 Hz	. 8	Yes	No
Li et al. (2013b)	Meth.	10	L DLPFC	1 Hz	1 day	No	Within subject

PFC, prefrontal cortex.



^eMultiple sessions were given in a single day.

bStudies used H-coil TMS devices (Brainsway, Jerusalem, Israel). This deep TMS coil geometry has a very different field distribution than the typical figure of eight coils.

Either Left or Right, Both High and Low Frequency rTMS of Dorsolateral Prefrontal Cortex Decreases Cue Induced Craving for Methamphetamine

(Lui et al., 2017)

50 males with MUD

Daily treatment for 5 days

Craving measured immediately before and 30 min after treatment







Figure 2. Repetitive Transcranial Magnetic Stimulation (rTMS) Intervention Effects on Withdrawal Symptoms, Craving, Quality of Sleep, Targeting Withdrawal Withdrawal symptoms Withdrawal symptoms **Symptoms in MUD:** Randomized Trial Liang et al., 2018


50 men with MUD

Sham-controlled


10 Hz trt L DLPFC


10 treatments over 12 days








B Cue-induced craving



















A, Withdrawal symptoms showed a significant difference for time ($F_{3.32} = 198.18$; P < .001; $p_2 = 0.81$) and for a time \times group interaction effect ($F_{3.12} = 198.18$) and for a time \times group interaction effect ($F_{3.12} = 198.18$) and for a time \times group interaction effect ($F_{3.12} = 198.18$) and for a time \times group interaction effect ($F_{3.12} = 198.18$) and for a time \times group interaction effect ($F_{3.12} = 198.18$) and for a time \times group interaction effect ($F_{3.12} = 198.18$) and for a time \times group interaction effect ($F_{3.12} = 198.18$) and for a time \times group interaction effect ($F_{3.12} = 198.18$) and $F_{3.12} = 198.18$ and $F_{3.12}$ P < .001; $n_0 2 = 0.31$). Post hoc t tests (with Bonferroni correction for multiple comparisons) showed that withdrawal symptoms were significantly reduced for both thereal rTMSgroup ($t_{23} = 13.21$; P < .001) and the shamrTMSgroup ($t_{21} = 9.53$, P < .001). B, Cue-induced craving showed a significant difference for time $(F_{3,132} = 50.52; P < .001; \eta_P 2 = 0.53)$ and for a time \times group interaction effect $(F_{3,132} = 22.93; P < .001; \eta_P 2 = 0.34)$. Post hoc t tests (with Bonferroni correction for

Repetitive transcranial magnetic stimulation treatment for female methamphetamine use disorder

Liu et al. 2019

90 MUD women

Treatment as usual (TAU) vs TAU plus rTMS

10 Hz DLPFC

#20 treatments over 4 weeks

Primary outcome: Craving

Measured pre, end of treatment, 60 days post







Fig. 3. The effect of rTMS in 10 Hz and control group. Inter group difference (# for p < .05, ## for p < .01 and ### for p < .001), and intra group difference (* for p < .05, ** for p < .01 and *** for p < .001) were showed. There were significant differences between 10 Hz group and control group at day 30/60 after the treatment (p < .001). The effect of time was also significant

TMS in Depression - Approved in 2008

- *****Still questions:
- *? Where to stimulate
- ? Accelerated treatment multiple treatments in 1 day, more rapid response
- ? Brain state at time of procedure
- Refining frequencies and patterns –Theta burst
- * ? Durability, maintenance





All good science leads to more questions: Currently approximately 220 TMS in SUD articles since 2000



- * Dose: 20 or more sessions in depression
- # Frequency: 10 Hz most commonly used
- * Target: DLPFC
- Durability
- # Impact on use (not only craving)
- ?Maintenance treatments
- * Adjunctive therapies



CTN 108: rTMS in Stimulant Use Disorder K Brady/M Trivedi Co-Pl

- **#**4 Site Trial
- *N=120, methamphetamine or cocaine use disorder
- *Daily digital monitoring of craving, use, mood/stress, sleep
- CBT digital modules available
- Primary Outcome: Feasibility of 30 sessions of rTMS (v. Sham)
- Secondary: Efficacy of up to 30 sessions of rTMS (v. Sham)
 - * Outcome: Percent negative of the last UDS per treatment week (7-day)





Clinical Trial of rTMS in Stimulant Use Disorder: TMS Parameters

- *30 sessions over 6-8 week period
- sessions offered daily, but allow for flexible delivery schedule; may have 2 sessions in 1 day, must have at least 4 sessions per week
- Coil placed over DLPFC using EEG coordinates, determine motor threshold weekly (more frequent if participant actively using)

- *Exploring EEG as biomarker for treatment efficacy
- Cue-reactivity session immediately before each TMS/sham session





ONWARD AND UPWARD

- Very promising therapy
- *MUCH progress made in last 20 years

- *****Need:
- * Sham controlled, adequate sample size
- Dose-comparison studies
- Durability studies
- Ancillary/concommitant treatment





References

- Hanlon CA, Dowdle LT, Henderson JS. Modulating Neural Circuits with Transcranial Magnetic Stimulation: Implications for Addiction Treatment Development. *Pharmacol Rev* 2018; **70**(3): 661-83.
- 2. Bolloni C, Panella R, Pedetti M, et al. Bilateral Transcranial Magnetic Stimulation of the Prefrontal Cortex Reduces Cocaine Intake: A Pilot Study. *Front Psychiatry* 2016; **7**: 133.
- 3. Liu T, Li Y, Shen Y, Liu X, Yuan TF. Gender does not matter: Add-on repetitive transcranial magnetic stimulation treatment for female methamphetamine dependents. *Prog Neuropsychopharmacol Biol Psychiatry* 2019; **92**: 70-5.
- 4. Liang Y, Wang L, Yuan TF. Targeting Withdrawal Symptoms in Men Addicted to Methamphetamine With Transcranial Magnetic Stimulation: A Randomized Clinical Trial. *JAMA Psychiatry* 2018; **75**(11): 1199-201.

